Covered recipient · General Payments record
BHAKTASHARAN C PATEL
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$2,371.87
69 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,371.87 | 69 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $356.29 | 10 |
| ABBVIE INC. | $335.08 | 13 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $252.19 | 5 |
| Madrigal Pharmaceuticals | $251.96 | 4 |
| Janssen Biotech, Inc. | $192.12 | 3 |
| Gilead Sciences, Inc. | $178.13 | 7 |
| Enterra Medical, Inc. | $138.85 | 3 |
| Boston Scientific Corporation | $124.88 | 1 |
| Lilly USA, LLC | $101.13 | 5 |
| Regeneron Pharmaceuticals, Inc. | $86.93 | 1 |
| Ardelyx, Inc. | $64.80 | 2 |
| Aimmune Therapeutics, Inc. | $59.22 | 3 |
| Takeda Pharmaceuticals U.S.A., Inc. | $46.11 | 2 |
| QOL Medical, LLC | $35.86 | 2 |
| Novo Nordisk Inc | $31.56 | 2 |
| Genentech, Inc. | $28.02 | 1 |
| Ipsen Biopharmaceuticals, Inc | $27.47 | 1 |
| Intercept Pharmaceuticals, Inc. | $17.34 | 1 |
| PFIZER INC. | $16.48 | 1 |
| Celltrion USA Inc. | $13.80 | 1 |
| Phathom Pharmaceuticals, Inc. | $13.65 | 1 |
Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BHAKTASHARAN C PATEL
NPI 1053415463 · CMS profile ID 183770
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
COLORADO SPRINGS, CO
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1053415463?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BHAKTASHARAN C PATEL, NPI 1053415463, CMS profile ID 183770. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1053415463?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). BHAKTASHARAN C PATEL, NPI 1053415463, CMS profile ID 183770. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1053415463?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- BHAKTASHARAN C PATEL, NPI 1053415463, CMS profile ID 183770, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1053415463?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
69 matching records · $2,371.87 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–69 of 69.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $111.41 | 03/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231818798 | CMS |
| Lilly USA, LLC | $19.44 | 03/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186465999 | CMS |
| QOL Medical, LLC | $18.91 | 03/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1185009110 | CMS |
| GENZYME CORPORATION | $6.35 | 03/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233435024 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.68 | 02/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231818792 | CMS |
| ABBVIE INC. | $19.95 | 02/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203496815 | CMS |
| GENZYME CORPORATION | $122.80 | 02/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233435020 | CMS |
| Lilly USA, LLC | $23.59 | 02/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186533661 | CMS |
| GENZYME CORPORATION | $26.81 | 02/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233435146 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $19.47 | 02/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223852769 | CMS |
| Janssen Biotech, Inc. | $18.72 | 02/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174898608 | CMS |
| Lilly USA, LLC | $22.09 | 02/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186526791 | CMS |
| Gilead Sciences, Inc. | $27.58 | 02/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234454439 | CMS |
| Aimmune Therapeutics, Inc. | $22.66 | 02/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1249655920 | CMS |
| Enterra Medical, Inc. | $22.03 | 02/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1253282971 | CMS |
| GENZYME CORPORATION | $4.53 | 02/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233435010 | CMS |
| Phathom Pharmaceuticals, Inc. | $13.65 | 01/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1219298951 | CMS |
| ABBVIE INC. | $18.44 | 01/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203496809 | CMS |
| Ipsen Biopharmaceuticals, Inc | $27.47 | 01/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1208832731 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $64.26 | 1 |
| PY2025 | Principal investigator | $1,147,400.95 | 447 |
| PY2024 | Recipient | $988.18 | 7 |
| PY2024 | Principal investigator | $1,506,607.67 | 224 |
| PY2023 | Recipient | $1,732.50 | 1 |
| PY2023 | Principal investigator | $1,888,822.04 | 111 |
| PY2022 | Principal investigator | $3,650,287.52 | 212 |
| PY2021 | Recipient | $289,855.91 | 4 |
| PY2021 | Principal investigator | $10,765,392.47 | 321 |
| PY2020 | Principal investigator | $2,106,543.20 | 148 |
| PY2019 | Recipient | $1,923.61 | 12 |
| PY2019 | Principal investigator | $883,667.25 | 120 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
448 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 12/29/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175183321 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,226.00 | 12/29/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175183365 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,407.00 | 12/29/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES PC | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis? | No dispute reported | 06/30/2026 | 1175417664 |
| Principal investigator 1 | Genentech, Inc. | $2,372.00 | 12/23/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A PHASE IIb TO ASSESS THE EFFICACY, SAFETY, AND PHARMAKOKINETICS OF RO7837195 in Patients with UC | No dispute reported | 06/30/2026 | 1211637263 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,491.10 | 12/19/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746976 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,073.54 | 12/19/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223289962 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $8,315.80 | 12/19/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050736 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,539.80 | 12/15/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Springs | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801108 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $96.90 | 12/11/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176547013 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $10,124.10 | 12/11/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050738 |
| Principal investigator 1 | ABBVIE INC. | $3,498.70 | 12/04/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES INC | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202528794 |
| Principal investigator 1 | ABBVIE INC. | $2,025.00 | 12/04/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202529000 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,441.40 | 12/04/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050740 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659074 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659076 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659078 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659080 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659082 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659084 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220747056 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220747058 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 12/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176547015 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,659.85 | 11/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746972 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,491.10 | 11/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746974 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $36,579.00 | 11/26/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. | No dispute reported | 06/30/2026 | 1235994754 |
| Principal investigator 1 | Genentech, Inc. | $6,728.00 | 11/25/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211637251 |
| Principal investigator 1 | Genentech, Inc. | $2,342.00 | 11/25/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | CD P3: Double-Blind Induction | No dispute reported | 06/30/2026 | 1211637258 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,154.25 | 11/25/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176547009 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,217.50 | 11/25/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050742 |
| Recipient | Eli Lilly and Company | $64.26 | 11/20/2025 | Covered Recipient Physician | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF LY4268989 (MORF-057) CO-ADMINISTERED WITH MIRIKIZUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1187870947 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $8,036.10 | 11/20/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050744 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,720.70 | 11/20/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050746 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.96 | 11/19/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746846 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 11/19/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746848 |
| Principal investigator 1 | Genentech, Inc. | $4,951.00 | 11/14/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | CD P3: Double-Blind Induction | No dispute reported | 06/30/2026 | 1211637256 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,354.10 | 11/14/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050748 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,427.98 | 11/07/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIAT | TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis | No dispute reported | 06/30/2026 | 1223288149 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $9,229.50 | 11/07/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050750 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $8,036.10 | 11/07/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050752 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 11/06/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220795263 |
| Principal investigator 1 | ABBVIE INC. | $2,565.00 | 11/05/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202523007 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,834.43 | 11/05/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192164079 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,471.31 | 11/05/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192164086 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,363.12 | 11/05/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192164095 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $13,192.46 | 11/05/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192164661 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,901.37 | 11/05/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIAT | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223288017 |
| Principal investigator 1 | ABBVIE INC. | $10,898.20 | 11/04/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES INC | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202520229 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659062 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659064 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659066 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659068 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659070 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659072 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220747052 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220747054 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 11/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176547011 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,223.00 | 10/31/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES PC | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis? | No dispute reported | 06/30/2026 | 1175417720 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $7,713.90 | 10/29/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050754 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $93.28 | 10/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659086 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 10/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659088 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $766.50 | 10/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659090 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.36 | 10/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659092 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.04 | 10/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659094 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,052.00 | 10/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746970 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 10/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183139 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,359.00 | 10/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183155 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 10/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183203 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,226.00 | 10/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175183248 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,226.00 | 10/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175183256 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,226.00 | 10/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175183288 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,359.00 | 10/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183330 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 10/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183349 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,625.00 | 10/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175183380 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,751.90 | 10/23/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050756 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,163.15 | 10/16/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176547005 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,073.54 | 10/16/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223287019 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,205.10 | 10/16/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050758 |
| Principal investigator 1 | ABBVIE INC. | $6,885.00 | 10/09/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202516315 |
| Principal investigator 1 | Genentech, Inc. | $4,585.00 | 10/09/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211637249 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,422.60 | 10/09/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050760 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,136.03 | 10/08/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF | No dispute reported | 06/30/2026 | 1192169216 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $6,463.80 | 10/03/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176547003 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659050 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659052 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659054 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659056 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659058 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659060 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220747048 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220747050 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 10/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176547007 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,024.00 | 09/29/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES PC | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants | No dispute reported | 06/30/2026 | 1175417725 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,392.90 | 09/26/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746962 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,052.00 | 09/26/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746964 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,883.25 | 09/26/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746966 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,052.00 | 09/26/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746968 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 09/24/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220747008 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 09/24/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220747010 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $21,525.00 | 09/23/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211637246 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $17,451.90 | 09/23/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050762 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,236.30 | 09/18/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050764 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,136.03 | 09/15/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF | No dispute reported | 06/30/2026 | 1192164639 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,121.95 | 09/12/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546999 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $12,998.50 | 09/12/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050734 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,692.00 | 09/05/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES PC | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants | No dispute reported | 06/30/2026 | 1175417654 |
| Principal investigator 1 | PFIZER INC. | $920.00 | 09/05/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228742608 |
| Principal investigator 1 | PFIZER INC. | $660.00 | 09/05/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228742944 |
| Principal investigator 1 | PFIZER INC. | $3,120.00 | 09/05/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228743055 |
| Principal investigator 1 | PFIZER INC. | $13,887.00 | 09/05/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228743251 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 09/05/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228743312 |
| Principal investigator 1 | PFIZER INC. | $900.00 | 09/05/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228743572 |
| Principal investigator 1 | PFIZER INC. | $20,259.00 | 09/05/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228754833 |
| Principal investigator 1 | PFIZER INC. | $4,500.00 | 09/05/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228755090 |
| Principal investigator 1 | PFIZER INC. | $2,360.00 | 09/05/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228755438 |
| Principal investigator 1 | PFIZER INC. | $8,007.00 | 09/05/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228755567 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 09/05/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228755837 |
| Principal investigator 1 | PFIZER INC. | $2,350.00 | 09/05/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228755968 |
| Principal investigator 1 | PFIZER INC. | $1,890.00 | 09/05/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228756560 |
| Principal investigator 1 | PFIZER INC. | $405.00 | 09/05/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228756724 |
| Principal investigator 1 | PFIZER INC. | $4,000.00 | 09/05/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228757249 |
| Principal investigator 1 | PFIZER INC. | $11,375.00 | 09/05/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228757263 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,913.88 | 09/05/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223285163 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,163.15 | 09/04/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546997 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $8,036.10 | 09/04/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050768 |
| Principal investigator 1 | ABBVIE INC. | $1,163.10 | 09/03/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202507587 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.79 | 09/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659012 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659024 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659026 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659028 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659030 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659032 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659048 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220747040 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220747042 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 09/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176547001 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,710.15 | 08/28/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746932 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,007.15 | 08/28/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746934 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,491.10 | 08/28/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746936 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,883.25 | 08/28/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746938 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,161.50 | 08/26/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746940 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.66 | 08/26/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746942 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 08/26/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746944 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 08/26/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746946 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $183.21 | 08/26/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746948 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $87.40 | 08/26/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746950 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.07 | 08/26/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746952 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.07 | 08/26/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746954 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.07 | 08/26/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746956 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.07 | 08/26/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746958 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.50 | 08/26/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746960 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $401.50 | 08/26/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220747006 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 08/26/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220747090 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,515.60 | 08/26/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050770 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,073.54 | 08/21/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223284467 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,769.00 | 08/21/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050772 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,112.10 | 08/14/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050774 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,136.03 | 08/12/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF | No dispute reported | 06/30/2026 | 1192167806 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $430.93 | 08/11/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546993 |
| Principal investigator 1 | Janssen Research & Development, LLC | $55,496.00 | 08/11/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES PC | A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175417694 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,515.60 | 08/07/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050776 |
| Principal investigator 1 | ABBVIE INC. | $7,190.00 | 08/06/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202503439 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659014 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659016 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659018 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659020 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659022 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659046 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220747036 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220747038 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 08/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546995 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,692.00 | 07/31/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES PC | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants | No dispute reported | 06/30/2026 | 1175417700 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $7,713.90 | 07/31/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050778 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,052.00 | 07/30/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746920 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,886.65 | 07/30/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746922 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,491.10 | 07/30/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746924 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7,936.65 | 07/30/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746926 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,785.05 | 07/30/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746928 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,052.00 | 07/30/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746930 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 07/28/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183108 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,359.00 | 07/28/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183115 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,955.00 | 07/28/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183193 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 07/28/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183314 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,551.60 | 07/22/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546987 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,121.95 | 07/22/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546991 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $21,356.80 | 07/22/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050780 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,136.03 | 07/17/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF | No dispute reported | 06/30/2026 | 1192169224 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $9,551.70 | 07/17/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050782 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,701.90 | 07/10/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050784 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,870.25 | 07/04/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223282242 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,031.20 | 07/04/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050786 |
| Principal investigator 1 | ABBVIE INC. | $9,061.10 | 07/02/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES INC | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202494627 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659034 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659036 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659038 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659040 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659042 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659044 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 07/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746840 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 07/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220747002 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220747044 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220747046 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 07/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546989 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 06/30/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175183132 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,226.00 | 06/30/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175183178 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,226.00 | 06/30/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175183374 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,244.00 | 06/30/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES PC | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Pa | No dispute reported | 06/30/2026 | 1175417649 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $116.60 | 06/24/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746836 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 06/24/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746838 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,883.25 | 06/24/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746882 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,886.65 | 06/24/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746884 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,007.15 | 06/24/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746886 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,052.00 | 06/24/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746888 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,785.05 | 06/24/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746890 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,710.15 | 06/24/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746892 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7,936.65 | 06/24/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746894 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,659.85 | 06/24/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746896 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,052.00 | 06/24/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746898 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,052.00 | 06/24/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746900 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,052.00 | 06/24/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746902 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,052.00 | 06/24/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746904 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,883.25 | 06/24/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746906 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,392.90 | 06/24/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746908 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.60 | 06/24/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220746998 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $85.60 | 06/24/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220747000 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.60 | 06/24/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220747086 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $85.60 | 06/24/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220747088 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,242.74 | 06/24/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546983 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $9,229.50 | 06/24/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050788 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,163.15 | 06/19/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546979 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,312.10 | 06/19/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546981 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,733.10 | 06/19/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050790 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,121.95 | 06/12/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546977 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,855.92 | 06/12/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223281090 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $7,172.80 | 06/12/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050792 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,438.37 | 06/10/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF | No dispute reported | 06/30/2026 | 1192167835 |
| Principal investigator 1 | ABBVIE INC. | $1,408.80 | 06/03/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202488249 |
| Principal investigator 1 | ABBVIE INC. | $18,239.20 | 06/03/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES INC | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202488251 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,492.44 | 06/02/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223280566 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659000 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659002 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659004 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659006 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659008 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220659010 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 06/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746844 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 06/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220747004 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220747032 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220747034 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 06/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546985 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,085.24 | 05/28/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223280372 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $15,427.80 | 05/28/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050794 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 05/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746910 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.21 | 05/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746912 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.21 | 05/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746914 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.21 | 05/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746916 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.21 | 05/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746918 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $151.58 | 05/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220746988 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 05/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220746990 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $620.50 | 05/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220746992 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.08 | 05/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220746994 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.00 | 05/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220746996 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $513.00 | 05/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546973 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,132.75 | 05/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546975 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $27,073.75 | 05/26/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192164071 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,512.00 | 05/23/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES PC | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants | No dispute reported | 06/30/2026 | 1175417714 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $33.71 | 05/22/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220747060 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.14 | 05/22/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220747062 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.86 | 05/22/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220747064 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $239.89 | 05/22/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220747066 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.52 | 05/22/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220747068 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.50 | 05/22/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220747070 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.50 | 05/22/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220747072 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.00 | 05/22/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220747074 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $7,713.90 | 05/22/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050766 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,955.00 | 05/12/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183264 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 05/12/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183279 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 05/12/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183305 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,359.00 | 05/12/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183342 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,359.00 | 05/12/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183358 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 05/12/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183395 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,136.03 | 05/09/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF | No dispute reported | 06/30/2026 | 1192112348 |
| Principal investigator 1 | ABBVIE INC. | $1,045.00 | 05/07/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202483279 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.89 | 05/07/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746826 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.79 | 05/07/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746828 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $147.49 | 05/07/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746830 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $147.49 | 05/07/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746832 |
| Principal investigator 1 | ABBVIE INC. | $1,778.60 | 05/06/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES INC | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202481767 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658988 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658990 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658992 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658994 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658996 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658998 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 05/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746834 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 05/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220746978 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 05/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220746980 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 05/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220746982 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $50.00 | 05/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220746984 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $28.00 | 05/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220746986 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220747028 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220747030 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 05/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546971 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,236.39 | 04/28/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, | No dispute reported | 06/30/2026 | 1192164098 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,272.05 | 04/28/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF | No dispute reported | 06/30/2026 | 1192164648 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,178.84 | 04/28/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223278676 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $151.58 | 04/23/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220747076 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 04/23/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220747078 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $620.50 | 04/23/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220747080 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.08 | 04/23/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220747082 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.00 | 04/23/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220747084 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $9,589.20 | 04/23/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546969 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,226.00 | 04/23/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175183124 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,226.00 | 04/23/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175183171 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 04/23/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175183271 |
| Principal investigator 1 | Eli Lilly and Company | $49,574.01 | 04/11/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | AN ADAPTIVE, DOSE-RANGING, PHASE 2 STUDY OF ELTREKIBART GIVEN ALONE OR IN COMBINATION WITH MIRIKIZUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1187890120 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,468.91 | 04/10/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192167819 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,132.75 | 04/08/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546963 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $4,230.97 | 04/08/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546965 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,551.60 | 04/08/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546967 |
| Principal investigator 1 | Bausch Health US, LLC | $2,457.00 | 04/02/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224843809 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658976 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658978 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658980 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658982 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658984 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658986 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 04/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746822 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220747024 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220747026 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 04/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546961 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,184.69 | 04/01/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223277248 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,122.00 | 03/31/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES PC | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants | No dispute reported | 06/30/2026 | 1175417707 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,746.22 | 03/26/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223277063 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.32 | 03/25/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746812 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 03/25/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746814 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $79.92 | 03/25/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746874 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $122.14 | 03/25/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746876 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.70 | 03/25/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746878 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.00 | 03/25/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746880 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,223.71 | 03/21/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192164635 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,121.95 | 03/19/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546957 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,588.86 | 03/19/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1223276773 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $6,114.20 | 03/11/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546953 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,312.10 | 03/11/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546955 |
| Principal investigator 1 | Janssen Research & Development, LLC | $43,747.00 | 03/10/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES PC | A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175417731 |
| Principal investigator 1 | ABBVIE INC. | $1,163.10 | 03/06/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202456284 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,245.32 | 03/06/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF | No dispute reported | 06/30/2026 | 1192167822 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,122.00 | 03/06/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES PC | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants | No dispute reported | 06/30/2026 | 1175417686 |
| Principal investigator 1 | PFIZER INC. | $1,550.00 | 03/03/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228784750 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658962 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658964 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658966 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658968 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658970 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658972 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 03/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746824 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220747020 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220747022 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 03/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546959 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183083 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,359.00 | 02/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183090 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183099 |
| Principal investigator 1 | Janssen Research & Development, LLC | $124.00 | 02/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183147 |
| Principal investigator 1 | Janssen Research & Development, LLC | $335.00 | 02/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183164 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183187 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183211 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,341.00 | 02/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183217 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 02/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183225 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,230.00 | 02/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183240 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,359.00 | 02/27/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175183295 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $48.29 | 02/25/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746794 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.98 | 02/25/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746800 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 02/25/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746802 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.81 | 02/25/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746804 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.81 | 02/25/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746806 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.81 | 02/25/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746808 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.81 | 02/25/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746810 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,245.32 | 02/24/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF | No dispute reported | 06/30/2026 | 1192167815 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,525.35 | 02/24/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192167830 |
| Principal investigator 1 | Janssen Research & Development, LLC | $23,755.00 | 02/24/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES PC | A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175417680 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $513.00 | 02/18/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546949 |
| Principal investigator 1 | Janssen Research & Development, LLC | $29,425.00 | 02/17/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES PC | A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175417672 |
| Principal investigator 1 | Bausch Health US, LLC | $1,910.00 | 02/07/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224843791 |
| Principal investigator 1 | Bausch Health US, LLC | $516.00 | 02/07/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224843794 |
| Principal investigator 1 | Celgene Corporation | $11,798.00 | 02/05/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. | No dispute reported | 06/30/2026 | 1222306751 |
| Principal investigator 1 | PFIZER INC. | $4,054.00 | 02/03/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228775237 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658950 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658952 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658954 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658956 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658958 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658960 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 02/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746842 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220747016 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220747018 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 02/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546951 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 01/31/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, | No dispute reported | 06/30/2026 | 1192112352 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $150.00 | 01/31/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, | No dispute reported | 06/30/2026 | 1192112359 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $10,000.00 | 01/31/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, | No dispute reported | 06/30/2026 | 1192164075 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $800.00 | 01/31/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, | No dispute reported | 06/30/2026 | 1192164083 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 01/31/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, | No dispute reported | 06/30/2026 | 1192164644 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,500.00 | 01/31/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, | No dispute reported | 06/30/2026 | 1192164657 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 01/31/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, | No dispute reported | 06/30/2026 | 1192164665 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $200.00 | 01/31/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, | No dispute reported | 06/30/2026 | 1192167811 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $161.20 | 01/31/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, | No dispute reported | 06/30/2026 | 1192167826 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $80.00 | 01/31/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, | No dispute reported | 06/30/2026 | 1192169228 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,500.00 | 01/31/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, | No dispute reported | 06/30/2026 | 1192169232 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 01/31/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, | No dispute reported | 06/30/2026 | 1192169240 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,028.00 | 01/31/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES PC | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants | No dispute reported | 06/30/2026 | 1175417659 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,226.00 | 01/30/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates Colorado Spgs | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175183387 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,132.75 | 01/29/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546947 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,474.39 | 01/28/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192164091 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,500.00 | 01/28/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, | No dispute reported | 06/30/2026 | 1192169212 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 01/28/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, | No dispute reported | 06/30/2026 | 1192169220 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 01/28/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, | No dispute reported | 06/30/2026 | 1192169236 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.24 | 01/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746796 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.24 | 01/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746798 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 01/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746816 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.24 | 01/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746818 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.24 | 01/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746820 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $104.94 | 01/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746850 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $179.82 | 01/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746852 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $730.00 | 01/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746854 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $549.63 | 01/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746856 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $262.20 | 01/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746858 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.05 | 01/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746860 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.49 | 01/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746862 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.49 | 01/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746864 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.49 | 01/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746866 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.49 | 01/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746868 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $21.96 | 01/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746870 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $52.50 | 01/27/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220746872 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $6,114.20 | 01/17/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546945 |
| Principal investigator 1 | Bausch Health US, LLC | $1,813.00 | 01/08/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224843799 |
| Principal investigator 1 | Bausch Health US, LLC | $1,615.00 | 01/08/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224843804 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,595.18 | 01/08/2025 | Non-covered Recipient Entity PEAK GASTROENTEROLOGY ASSOCIATES | PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF | No dispute reported | 06/30/2026 | 1192164652 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,469.60 | 01/07/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546941 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,950.68 | 01/07/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546943 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658940 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658942 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658944 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658946 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658948 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates-Briargate | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220658974 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 01/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220746792 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220747012 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Future Innovative Treatments LLC | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220747014 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 01/01/2025 | Non-covered Recipient Entity Peak Gastroenterology Associates, Pc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546939 |